Overexpression of LSD1 can strongly inhibit p53 in prostate cancer (PCa) and promote androgen-independent (AI) transformation of PCa and LNCaP cells in an androgen-deficient setting (Li X. et al., 2016). The gene discussed is TP53; the disease is posterior cortical atrophy.